![Filip Janku](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Filip Janku
Hoofd Techniek/Wetenschap/O&O bij
MONTE ROSA THERAPEUTICS, INC.
Vermogen: 1 M $ op 31-05-2026
Profiel
Dr. Filip Janku is a Chief Medical Officer at Monte Rosa Therapeutics, Inc. Dr. Janku was previously employed as a Center Medical Director & Associate Professor by The University of Texas M.D.
Anderson Cancer Center.
He received his doctorate degree from the University of Charles.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 30-06-2026 | 60.612 ( 0,07% ) | 1 M $ | 31-05-2026 |
Actieve functies van Filip Janku
| Bedrijven | Functie | Begin |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-06-2021 |
Eerdere bekende functies van Filip Janku
| Bedrijven | Functie | Einde |
|---|---|---|
The University of Texas M.D. Anderson Cancer Center
 The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services Provides cancer patient care, research and prevention for cancer | Corporate Officer/Principal | 01-05-2021 |
Opleiding van Filip Janku
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
5
Eerstegraads connecties
3
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services Provides cancer patient care, research and prevention for cancer | Consumer Services |
University of Charles
 University of Charles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Monte Rosa Therapeutics, Inc.
 Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
